E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells.
Moriya, Junji, Chen, Rui, Yamakawa, Jun-ichi et al. · Biological & pharmaceutical bulletin · 2011 · DOI
Quick Summary
Researchers created mice with chronic fatigue by repeatedly exposing them to a bacterial antigen, which caused them to move less and their brains to shrink in a region called the hippocampus. When they gave these mice resveratrol (a compound found in red grapes), the mice became more active and their hippocampus enlarged. The treatment appeared to work by reducing brain cell death and promoting the growth of new brain cells.
Why It Matters
ME/CFS patients often experience cognitive dysfunction and neuroimaging shows hippocampal abnormalities, yet mechanisms are poorly understood. This study identifies a potential therapeutic target (neurogenesis and apoptosis inhibition) and demonstrates that a naturally occurring compound may reverse hippocampal damage, providing preliminary rationale for investigating similar approaches in human patients.
Observed Findings
- Daily running activity increased by more than 20% in resveratrol-treated fatigue mice compared to untreated controls.
- Hippocampal volume enlarged following 4 weeks of resveratrol therapy in previously atrophied hippocampi.
- Resveratrol inhibited neuronal apoptosis and reduced hippocampal acetylated p53 expression in fatigue mice.
- Resveratrol improved neurogenesis markers and increased brain-derived neurotrophic factor mRNA expression in the hippocampus.
Inferred Conclusions
- Repeated Brucella abortus antigen injection reliably induces a chronic fatigue phenotype with structural brain changes in mice.
- Resveratrol may reverse fatigue-associated hippocampal atrophy through dual mechanisms: suppression of cell death and promotion of new neuronal growth.
- Sirtuin 1 activation via resveratrol may represent a therapeutic strategy for fatigue-related neurobiological abnormalities.
Remaining Questions
- How well does the Brucella-antigen mouse model replicate the underlying pathophysiology of human ME/CFS?
- Would resveratrol be effective in human ME/CFS patients, and at what doses and treatment duration?
- Are the observed changes in neurogenesis and apoptosis directly responsible for fatigue improvement, or are they secondary markers?
What This Study Does Not Prove
This study does not prove that resveratrol is effective in humans with ME/CFS—it is only an animal model study. It does not establish that bacterial antigens cause human ME/CFS, nor does it prove that hippocampal atrophy is the primary cause (rather than consequence) of fatigue. The findings suggest a possible mechanism but require human clinical trials before clinical recommendations can be made.
Tags
Symptom:Fatigue
Biomarker:NeuroimagingGene ExpressionBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedSmall SampleExploratory Only
Metadata
- DOI
- 10.1248/bpb.34.354
- PMID
- 21372384
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →